Abstract: Methods for detecting urogenital conditions or urogenital status in a subject are described comprising measuring urogenital markers or polynucleotides, encoding the markers in a sample from the subject. The invention also provides localization or imaging methods for urogenital conditions, and kits for carrying out the methods of the invention. The invention also contemplates therapeutic applications for urogenital conditions employing urogenital markers, polynucleotides encoding the markers, and/or binding agents for the markers.

Abstract: Methods for detecting urogenital conditions or urogenital status in a subject are described comprising measuring urogenital markers or polynucleotides, encoding the markers in a sample from the subject. The invention also provides localization or imaging methods for urogenital conditions, and kits for carrying out the methods of the invention. The invention also contemplates therapeutic applications for urogenital conditions employing urogenital markers, polynucleotides encoding the markers, and/or binding agents for the markers.

Abstract: Methods for detecting urogenital conditions or urogenital status in a subject are described comprising measuring urogenital markers or polynucleotides, encoding the markers in a sample from the subject. The invention also provides localization or imaging methods for urogenital conditions, and kits for carrying out the methods of the invention. The invention also contemplates therapeutic applications for urogenital conditions employing urogenital markers, polynucleotides encoding the markers, and/or binding agents for the markers.

Abstract: Methods for detecting urogenital conditions or urogenital status in a subject are described comprising measuring urogenital markers or polynucleotides encoding the markers in a sample from the subject. The invention also provides localization or imaging methods for urogenital conditions, and kits for carrying out the methods of the invention. The invention also contemplates therapeutic applications for urogenital conditions employing urogenital markers, polynucleotides encoding the markers, and/or binding agents for the markers.

Abstract: A method of evaluating a probability a subject has a cancer, diagnosing a cancer and/or monitoring cancer progression comprising: a. measuring an amount of a biomarker selected from the group consisting of CUZD1 and/or LAMC2 and/or the group CUZD1, LAMC2, AQP8, CELA2B, CELA3B, CTRB1, CTRB2, GCG, IAPP, INS, KLK1, PNLIPRP1, PNLIPRP2, PPY, PRSS3, REG3G, SLC30A8, KLK3, NPY, PSCA, RLN1, SLC45A3, DSP, GP73, DSG2, CEACAM7, CLCA1, GPA33, LEFTY1, ZG16, IRX5, LAMP3, MFAP4, SCGB1A1, SFTPC, TMEM100, NPY, PSCA, RLN1 and/or SLC45A3 in a test sample from a subject with cancer; wherein the cancer is pancreas cancer if CUZD1, LAMC2, AQP8, CELA2B, CELA3B, CTRB1, CTRB2, GCG, LAPP, INS, KLK1, PNLIPRP1, PNLIPRP2, PPY, PRSS3, REG3G, SLC30A8, DSP, GP73 and/or DSG2 is selected; the cancer is colon cancer if CEACAM7, CLCA1, GPA33, LEFTY1 and/or ZG16 is selected, the cancer is lung cancer if IRX5, LAMP3, MFAP4, SCGB1A1, SFTPC and/or TMEM100 is selected; or the cancer is prostate cancer if NPY, PSCA, RLN1 and/or SLC45A3 is selected; b.

Abstract: The disclosure includes assays and methods for screening for risk of Down syndrome and/or trisomy 21 in a fetus. The assays and methods comprise determining the level of at least one biomarker selected from mucin 13 (MUC13), bile salt-activated lipase (CEL), dipeptidyl peptidase 4 (DPP4), carboxypeptidase A1 (CPA1), amyloid precursor protein (APP) and tenascin-C (TNC-C) polypeptides in a test biological sample from a pregnant subject, wherein a decreased level of MUC13, CEL, DPP4, and/or CPA1 polypeptide and/or an increased level of APP and/or TNC-C polypeptide in the test biological sample compared to a corresponding reference biomarker polypeptide level indicates an increased risk of Down syndrome or trisomy 21 in the fetus. The disclosure also includes assays, compositions, immunoassays, and kits for performing the methods disclosed herein.

Abstract: Methods for detecting urogenital conditions or urogenital status in a subject are described comprising measuring urogenital markers or polynucleotides encoding the markers in a sample from the subject. The invention also provides localization or imaging methods for urogenital conditions, and kits for carrying out the methods of the invention. The invention also contemplates therapeutic applications for urogenital conditions employing urogenital markers, polynucleotides encoding the markers, and/or binding agents for the markers.

Abstract: The disclosure includes assays and methods for screening for risk of Down syndrome and/or trisomy 21 in a fetus. The assays and methods comprise determining the level of at least one biomarker selected from mucin 13 (MUC13), bile salt-activated lipase (CEL), dipeptidyl peptidase 4 (DPP4), carboxypeptidase A1 (CPA1), amyloid precursor protein (APP) and tenascin-C (TNC-C) polypeptides in a test biological sample from a pregnant subject, wherein a decreased level of MUC13, CEL, DPP4, and/or CPA1 polypeptide and/or an increased level of APP and/or TNC-C polypeptide in the test biological sample compared to a corresponding reference biomarker polypeptide level indicates an increased risk of Down syndrome or trisomy 21 in the fetus. The disclosure also includes assays, compositions, immunoassays, and kits for performing the methods disclosed herein.

Abstract: A method of screening for, diagnosing or detecting lung cancer in a subject, the method comprising: a) determining a level of a biomarker or a plurality of biomarkers in a sample from the subject, wherein the biomarker(s) is/are selected from the biomarkers listed in Table 8, and b) comparing the level of each biomarker in the sample with a control; wherein an increased level of any one of the biomarkers compared to the control is indicative that the subject has lung cancer Biomarkers were identified by shot-gun proteomics analysis of lung cancer cell-lines H1688, H520, H460 and H23. These lines are of differing histo-types, and were grown on serum-free media.

Abstract: Provided is a method of screening for, diagnosing or detecting ovarian cancer in a subject comprising (a) determining a level of mdogen-2 in a test sample from the subject, and (b) comparing the level of mdogen-2 in the test sample with a control, where detecting an increase in the level of mdogen-2 in the test sample compared to the control is indicative of ovarian cancer in the subject.

Abstract: The present application describes biomarkers and methods useful for screening for, diagnosing or detecting the presence and severity of breast cancer in a subject. The present application also provides methods for determining the prognosis of a subject with breast cancer as well as methods for monitoring the therapeutic response to a breast cancer treatment or therapy.

Abstract: A method for the diagnosis, prognosis, and monitoring of ovarian cancer in a subject by detecting hK10 in a sample from the subject, preferably a serum sample or tumor tissue extract. hK10 may be measured using a reagent that detects or binds to hK10 preferably antibodies specifically reactive with hK10 or a part thereof. Imaging methods for tumors associated with hK10 are also described using an agent that binds to hK10 which had a label for imaging the tumor.

Abstract: The invention relates to a kallikrein protein, compositions comprising the protein, and the use thereof.

Abstract: The present invention relates to nucleic acid molecules, encoding kallikrein 15, a novel member of the kallikrein family. Also provided herein are vectors and host cells comprising the nucleic acid molecules, and methods for producing kallikrein 15 proteins.

Abstract: The invention relates to nucleic acid molecules, kallikrein-like proteins encoded by such nucleic acid molecules; and use of the proteins and nucleic acid molecules.

Abstract: Methods for diagnosing and monitoring Alzheimer's Disease in a subject comprising measuring hK6 in a sample from the subject. hK6 may be measured using a reagent that detects or binds to hK6, preferably antibodies reactive with hK6.

Abstract: A method for the diagnosis, prognosis, and monitoring of ovarian cancer in a subject by detecting hK10 in a sample from the subject, preferably a serum sample or tumor tissue extract, hK10 may be measured using a reagent that detects or binds to hK10 preferably antibodies specifically reactive with hK10 or apart thereof. Imaging methods for tumors associated with hK10 are also described using an agent that binds to hK10 which has a label for imaging the tumor.

Abstract: A method for the diagnosis, prognosis, and monitoring of ovarian cancer in a subject by detecting hK6 in a sample from the subject, preferably a serum sample or tumor tissue extract. hK6 may be measured using a reagent that detects or binds to hK6 preferably antibodies specifically reactive with hK6 or a part thereof. Imaging methods for tumors associated with hK6 are also described using an agent that binds to hK6 which has a label for imaging the tumor.

Abstract: The invention relates to nucleic acid molecules. proteins encoded by such nucleic acid molecules: and use of the proteins and nucleic acid molecule.

Abstract: Proteins that trigger immune responses in cancer patients are described. The proteins include protein phosphatase 4 regulatory subunit (Genbank AJ271448); a protein product corresponding to Genbank AK001674; putative translation initiation factor (SUI1) (Genbank NM-005801); RNA helicase (Genbank AL359945); MIL1 protein, nuclear gene encoding mitochondrial protein (NM-015367); MacMarks protein (Genbank X70326); chromosome 11 open reading frame 10 (c11orf10) (Genbank AF0867763); and, plakophilin 4 (PKP4) (Genbank NM-003628). In addition, a novel nucleic acid molecule identified in an immunoscreen of a breast carcinoma cDNA library is described. Diagnostic and therapeutic applications are also described.